Acumen price target raised to $7 from $4 at BTIG

BTIG raised the firm’s price target on Acumen (ABOS) to $7 from $4 and keeps a Buy rating on the shares. The rollout of Biogen’s (BIIB) two commercial drugs LEQEMBI and KISUNLA has been slow, partially due to the infusions required to deliver these drugs, but the news that the FDA has accepted sBLA for LEQEMBI SubQ induction therapy with priority review status is a “nice positive for the future of the field” in Alzheimer’s disease treatment, the analyst tells investors in a research note.